Indegene — Q4 FY26 earnings call

Call held 30 Apr 2026

Management summary

Indegene reported a milestone Q4 and full year FY26, with revenues exceeding ₹1,000 crores and ₹3,500 crores respectively for the first time, driven by strong customer growth and strategic GenAI-led innovation. Adjusted EBITDA showed robust growth, and cash generation was strong. However, reported PAT was impacted by one-time charges related to currency volatility and a legal settlement, though adjusted PAT showed positive growth. The company expressed confidence in FY27 growth, driven by scaling current initiatives and strategic acquisitions.

Highlights

  • Q4 FY26 revenue of ₹10,000 million, growing 32.8% YoY and 6.5% QoQ, marking the first time revenues exceeded ₹1,000 crores.

  • Full year FY26 revenue of ₹35,105 million, growing 23.6% YoY in INR terms and 18.2% in USD terms, crossing ₹3,500 crores for the first time.

  • Q4 FY26 adjusted EBITDA of ₹1,889 million, up 23.2% YoY, and full year adjusted EBITDA of ₹6,793 million, up 20.8% YoY.

  • Strong cash generation with FY26 operating cash flows at ₹6,508 million (162% of PAT) and free cash flows at ₹6,065 million.

  • Significant customer expansion: total active customer base grew from 73 to 91, and the number of customers contributing over $1 million in annual revenue increased by 30% from 41 to 53.

  • Successful integration of BioPharm ahead of schedule, with G&A synergies expected in the next quarter.

Concerns

  • Q4 FY26 PAT was ₹797 million and full year PAT declined 1.4% to ₹4,011 million, impacted by one-time items.

  • An incremental charge of ₹241 million in Q4 due to INR depreciation against USD on unexpired forward contracts.

  • A one-time provision of ₹203 million for the estimated settlement of a US class action lawsuit from 2020.

Key financials

6 periods

Headline

  • Revenue per Employee (Current)
    75,000 USD

Q4 FY26

  • Revenue
    10,000 Mn
    YoY +32.8% QoQ +6.5%
  • Adjusted EBITDA
    1,889 Mn
    YoY +23.2%
  • Reported EBITDA
    1,648 Mn
  • PAT
    797 Mn

Q4 FY26 CC QoQ

  • Organic Growth
    0.03 qoq_pct

Q4 FY26 CC YoY

  • Organic Growth
    0.12 yoy_pct

FY26

  • Revenue
    35,105 Mn
    YoY +23.6%
  • Adjusted EBITDA
    6,793 Mn
    YoY +20.8%
  • PAT
    4,011 Mn
    YoY -1.4%
  • Adjusted PAT
    4,583 Mn
    YoY +12.7%
  • Operating Cash Flow
    6,508 Mn
  • Free Cash Flow
    6,065 Mn

FY26 End

  • Cash & Investments
    15,385 Mn

What they filed

Q1 FY27: revenue up 33.2%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue282 287 267 256 307 +9%290 +1%368 +38%341 +33%
EBITDA46 52 40 37 71 +54%38 −27%103 +158%60 +62%
Net profit45 50 54 45 60 +33%35 −30%72 +33%60 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Enterprise Commercial (ex-BioPharm)
    0.17 yoy_pct Revenue Growth
  • Enterprise Medical Services (EMS)
    0.16 yoy_pct Revenue Growth
  • BioPharm
    0.15 qoq_pct Revenue Growth
  • North America
    71.6% Share of Revenue
  • Europe
    25.5% Share of Revenue
  • Rest of World
    2.9% Share of Revenue

Capital allocation

high confidence
  • Dividend ₹2.25/share (final)
    With this, let me move on to the dividend announcement. Consistent with this cash strength and reflecting the Board's confidence in the business, we have proposed a final dividend of ₹2.25 per equity share for FY26. This compares to 2 per share last year, a 12.5% increase. This recommendation is subject to shareholders' approval at the upcoming AGM and reflects both the strength of our FY26 earnings and our commitment to delivering consistent returns to shareholders alongside continued investments.
  • M&A BioPharm Acquisition · Integrated

    strengthened our omnichannel data and targeting capabilities in the commercial segment

    BioPharm acquired in October 2025 grew by 15% sequentially in Q4.

    We made 3 acquisitions. BioPharm strengthened our omnichannel data and targeting capabilities in the commercial segment.
  • M&A Warn Communications Acquisition · Closed

    strategic additions of people with deep expertise and local market knowledge in key European geographies

    Warn and Cake Communications are not new market entries, they are strategic additions of people with deep expertise and local market knowledge in key European geographies.
  • M&A Cake Communications Acquisition · Closed

    strategic additions of people with deep expertise and local market knowledge in key European geographies

    Warn and Cake Communications are not new market entries, they are strategic additions of people with deep expertise and local market knowledge in key European geographies.
  • Liquidity Cash ₹15,385 Mn Closed FY26 with a cash and investment position of approximately ₹15,385 million, just ₹1,258 million lower than FY25 despite ₹7,253 million of outflows towards the acquisitions made during the year.
    Our balance sheet at the year-end reflects this trend. We closed FY26 with a cash and investment position of approximately 15,385 million, just ₹1,258 million lower than FY25 despite ₹7,253 million of outflows towards the acquisitions that we made during the year.

Guidance & targets

Customer Growth

  • Largest customer revenue Customer Growth · FY27 · Medium confidence $50 million-plus
    And FY27 is where we expect it to convert into visible growth and we are hoping this customer is going to cross over and become our first $50 million-plus customer.

    — Manish Gupta

Revenue Conversion

  • Multiyear omnichannel deal (>$10M ACV) Revenue Conversion · H2 FY27 · High confidence Converting to revenue
    The latter half of FY27 will see this deal converting to revenue.

    — Manish Gupta

Profitability

  • EBITDA margins Profitability · H2 FY27 · Medium confidence Revert to earlier levels of higher margins
    With the growth momentum, we believe that we are on track to improve our profitability and EBITDA margins in FY27 and the second half of FY27 will see us revert to the earlier levels of higher margins with these investments getting fully absorbed and delivering growth.

    — Suhas Prabhu

  • PAT Profitability · FY27 · Medium confidence Significant upward movement
    Amortization stabilizing and coming off towards the latter half of FY27 and the impact of the one-off and exceptional items fading away, we believe that PAT in FY27 will see a significant upward movement.

    — Suhas Prabhu

Industry Growth

  • Pharma Industry CAGR Industry Growth · 2026 to 2028 · High confidence 5% to 8%
    Looking ahead, the industry is positioned to grow at a healthy 5% to 8% CAGR from 2026 to 2028.

    — Manish Gupta

Working Capital

  • Debtor days Working Capital · steady basis · Medium confidence mid-60s to 70 days
    But having said that, I would guide towards mid-60s to 70 days on a steady basis.

    — Suhas Prabhu

Operational Efficiency

  • G&A synergies from BioPharm integration Operational Efficiency · next quarter · High confidence Immediate impact
    But G&A would be the immediate impact that we anticipate to see coming in the next quarter itself.

    — Suhas Prabhu

Revenue Recognition

  • $10 million Q3 win Revenue Recognition · FY27 · High confidence Entirely recognized
    One last final comment- that $10 million win that we had mentioned in quarter 3, while it has kicked off and started. From a revenue recognition perspective, it is deferred because this is an outcome-based pricing model and will be entirely recognized in FY27.

    — Suhas Prabhu

What to watch in Q1 FY27

G&A synergies from BioPharm integration

next quarter
Current Integration completed, synergies anticipated
Target Positive impact on G&A

Why it matters

Immediate impact on profitability from recent acquisition integration.

But G&A would be the immediate impact that we anticipate to see coming in the next quarter itself.

Risks & concerns

  • Currency volatility impacting profitability

    medium

    INR depreciation against USD resulted in an incremental charge of ₹241 million in Q4 on unexpired forward contracts.

    Management acknowledged

  • US class action lawsuit settlement

    medium

    A one-time provision of ₹203 million was made for the estimated cost of settling a 2020 lawsuit alleging breach of TCPA.

    Management acknowledged

  • Commoditization of AI domain knowledge

    low

    Analyst questioned if large LLMs could commoditize Indegene's domain expertise; management asserted its moats are strong due to deep domain knowledge, proprietary data, and human-in-the-loop workflows in regulated areas.

    Analyst downplayed

Q&A highlights

7 direct
Revenue per employee growth and drivers Direct
our RPEs have consistently grown from $51,000 to close to $75,000 today and also from $66,000 to $75,000 on a year-on-year basis.

Clarifies the significant increase in revenue per employee, attributing it to technology, AI, outcome-based pricing, and strategic engagements rather than just on-site mix.

Asked by Prakash Kapadia

Growth in $10M+ revenue client cohort Partial
I'll start off with latter one and pass it on to Suhas. We hear that cohort is stable. It's also a function that at least one of our clients was just tad below that $10 million.

Addresses why the number of $10M+ clients hasn't increased, indicating one client was just below the threshold and that growth is expected but subject to client internal change management cycles.

Asked by Prakash Kapadia

Defendability of AI moats against commoditization Direct
Our real moat over here, which we continue to invest and solidify every day is domain expertise. And domain expertise is just not a very broad term. ... So at least in the medium term, call it 3 to 5 years, we don't see LLMs having the ability to do this.

Management defends its competitive advantage in AI by emphasizing deep domain expertise, proprietary data sources, and the need for human-in-the-loop workflows in regulated life sciences, differentiating from generic LLM applications.

Asked by Prolin Nandu

Impact of AI investments on margins and operating leverage Direct
We have baked in a bunch of investments. This year, our R&D cost as we call it, has gone up. It's tad above 2% of our revenues. ... And one reason why we're not saying that our margins will expand beyond what they used to be, while there might be leverage over there, is because we believe that anything above that range we are operating in, we are going to reinvest in the business.

Explains that current investments in AI and GTM are impacting margins, but these are strategic for future growth, and any operating leverage gains will be reinvested to maintain competitiveness.

Asked by Prolin Nandu

FY27 growth drivers and strategy Direct
FY27 is going to be more a year of scaling what we did in FY26. In FY26, we did a bunch of things different. We made investment in talent, we crystallized on solutions with bunch of our clients across the board. We won some very marquee engagements I spoke about earlier.

Outlines the strategy for FY27 as scaling successful FY26 initiatives, including GenAI-led wins, Tectonic engagements, and leveraging strategic acquisitions, rather than pursuing entirely new directions.

Asked by Raghav Maheshwari

Solutions for generic and small-sized companies Direct
Mid-sized and small companies is something which we are expanding rapidly. We are seeing significant traction. ... As far as generics are concerned, we do some work with them. ... But if I just contrast the opportunity we have with innovative pharma companies, where, as I mentioned earlier that we believe we will have $100 million clients in some years versus the other part. So, we want to prioritize the resources accordingly.

Clarifies the company's approach to smaller clients, indicating expansion into this segment with specific offerings like product launches, but prioritizing innovative pharma due to larger revenue potential.

Asked by Lakshminarayanan

Organic growth in constant currency for Q4 FY26 Direct
Constant currency terms year-on-year growth has been 12% organic and a little north of 3% QoQ.

Provides specific organic growth figures, which are crucial for assessing underlying business health separate from acquisitions and currency effects.

Asked by Yash Mehta

Margin outlook for FY27 considering BioPharm integration Direct
So, the integration of BioPharm was successfully completed ahead of schedule towards the end of February. The transition services from the seller was originally planned to get concluded end of March. This completion of the transition would be adding to basically synergies on the G&A side. But as we speak, we are also looking at synergies on the data subscriptions, on the business operations, and eventually go-to-market. And we would progressively start impacting us through the quarters in FY27 more positively.

Details the expected positive impact of BioPharm integration on margins, starting with G&A synergies in the next quarter and broader operational synergies throughout FY27.

Asked by Yash Mehta

2 min read 5 chapters

Detailed narrative

Q4 and Annual FY26 Financial Performance Highlights

Indegene achieved significant milestones in Q4 FY26, with revenues exceeding ₹1,000 crores (₹10,000 million) for the first time, representing a 32.8% YoY and 6.5% QoQ growth. For the full fiscal year, revenues crossed ₹3,500 crores (₹35,105 million), growing 23.6% in INR and 18.2% in USD terms. Adjusted EBITDA for Q4 stood at ₹1,889 million (up 23.2% YoY) and for FY26 at ₹6,793 million (up 20.8% YoY). Despite these strong operational results, reported PAT for FY26 declined 1.4% to ₹4,011 million, primarily due to a ₹241 million charge from currency volatility and a ₹203 million provision for a legal settlement.

Customer Portfolio Expansion and Deepening

The company demonstrated robust customer growth and deepening relationships in FY26. The total active customer base expanded from 73 to 91, while the number of customers contributing over $1 million in annual revenue increased by approximately 30%, from 41 to 53. This growth in the mid-tier cohort outpaced the top 20, validating Indegene's 'land and expand' model. Management highlighted that this diversification ensures the business is not top-heavy and builds a durable portfolio, with several newer relationships already scaling to $5 million ACV engagements.

GenAI-led Innovation and Competitive Differentiators

Indegene emphasized its decade-long investment in AI, which is now yielding significant wins and driving productivity, with revenue per employee reaching $75,000 per annum, up from $56,000 three years prior. Key GenAI-powered solutions include an omnichannel orchestration deal with a top 5 customer, end-to-end commercialization for a mid-sized biotech, and AI-driven pharmacovigilance. The company differentiates itself through deep domain knowledge, proprietary data, and agentic human-in-the-loop workflows, which are critical in the highly regulated life sciences sector where LLMs alone are insufficient.

Strategic Acquisitions and Market Positioning

In FY26, Indegene completed three strategic acquisitions: BioPharm, Warn Communications, and Cake Communications, with total outflows of ₹7,253 million for acquisitions during the year. BioPharm strengthened omnichannel data capabilities, while Warn and Cake enhanced European market presence and expertise. These acquisitions, along with initiatives like 'Tectonic' (GenAI with creative expertise), are positioning Indegene as a strategic operating partner for life sciences, taking share from traditional agencies and CROs, and expanding its addressable market through AI-led operating models.

FY27 Outlook and Growth Drivers

Management expressed confidence for FY27, citing a stronger and higher pipeline across both top 20 and outside top 20 customers. Key growth drivers include the scaling of GenAI-led solutions, the Tectonic model, and the conversion of strategic deals into revenue, such as a multiyear omnichannel deal expected to convert in H2 FY27. The company anticipates improved profitability and EBITDA margins in FY27, with PAT seeing significant upward movement as one-time impacts fade and amortization stabilizes. The pharma industry is projected to grow at a healthy 5-8% CAGR from 2026-2028, providing a favorable backdrop.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls